Zacks: Brokerages Expect Genocea Biosciences (GNCA) Will Announce Earnings of -$0.14 Per Share

Wall Street analysts predict that Genocea Biosciences (NASDAQ:GNCA) will announce ($0.14) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Genocea Biosciences’ earnings, with estimates ranging from ($0.15) to ($0.13). Genocea Biosciences posted earnings of ($0.54) per share during the same quarter last year, which would suggest a positive year over year growth rate of 74.1%. The company is expected to announce its next earnings report on Wednesday, August 8th.

According to Zacks, analysts expect that Genocea Biosciences will report full year earnings of ($0.68) per share for the current fiscal year, with EPS estimates ranging from ($0.74) to ($0.62). For the next financial year, analysts anticipate that the business will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.86) to ($0.60). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Genocea Biosciences.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.14) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.14).

Several analysts have commented on GNCA shares. HC Wainwright set a $5.00 price objective on shares of Genocea Biosciences and gave the stock a “buy” rating in a report on Thursday, May 10th. Zacks Investment Research upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating in a report on Wednesday, April 18th. Cantor Fitzgerald set a $5.00 price objective on shares of Genocea Biosciences and gave the stock a “buy” rating in a report on Sunday, March 11th. ValuEngine upgraded shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Finally, Robert W. Baird started coverage on shares of Genocea Biosciences in a report on Monday, February 12th. They issued an “outperform” rating and a $3.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Genocea Biosciences presently has an average rating of “Buy” and a consensus price target of $4.41.

Hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC purchased a new position in shares of Genocea Biosciences during the fourth quarter valued at approximately $145,000. California State Teachers Retirement System lifted its holdings in shares of Genocea Biosciences by 166.6% during the first quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 78,469 shares during the last quarter. Schwab Charles Investment Management Inc. purchased a new position in shares of Genocea Biosciences during the first quarter valued at approximately $177,000. Birchview Capital LP lifted its holdings in shares of Genocea Biosciences by 384.6% during the first quarter. Birchview Capital LP now owns 189,000 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 150,000 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its holdings in shares of Genocea Biosciences by 266.9% during the first quarter. GSA Capital Partners LLP now owns 234,065 shares of the biotechnology company’s stock valued at $246,000 after purchasing an additional 170,265 shares during the last quarter. Hedge funds and other institutional investors own 61.94% of the company’s stock.

GNCA traded down $0.02 on Friday, hitting $0.93. The company had a trading volume of 466,899 shares, compared to its average volume of 974,686. The company has a debt-to-equity ratio of 1.00, a current ratio of 8.06 and a quick ratio of 8.06. Genocea Biosciences has a 52-week low of $0.79 and a 52-week high of $6.78. The firm has a market capitalization of $83.91 million, a PE ratio of -0.47 and a beta of 1.20.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform AnTigen Lead Acquisition System to design immunotherapies and vaccines that act through T cell immune responses. Its lead product candidate is GEN-003, an investigational immunotherapy that is in Phase III trial for the treatment of genital herpes infections.

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply